Group 1: Company Strategy and Market Position - The company is developing post-medical insurance negotiation strategies and sales plans, emphasizing the competitive advantages of its product 康柏西普 (Conbercept) due to its proven efficacy and quality [4] - 康柏西普's global multi-center phase III clinical trials have commenced in over 30 countries with more than 300 research centers, with participant enrollment expected to complete by January 2020 [4][5] - The company plans to communicate with regulatory bodies like the U.S. FDA and European Medicines Agency regarding the clinical trial protocols for new indications [5] Group 2: Financial and Investment Updates - On November 8, 2019, the China Securities Regulatory Commission approved the company's application for a public offering of convertible bonds, pending formal approval [6] - The major shareholder plans to participate in the subscription of the convertible bonds [6] - As of November 29, 2019, the major shareholder, 鼎晖维鑫, has reduced its holdings to 15,275,400 shares, representing 1.7446% of the total shares [8] Group 3: Research and Development - The company has maintained a research and development expense ratio of around 12% in 2017 and 2018, with expectations for continued growth in R&D investment in the coming years [8] - The Beijing R&D center is crucial for the global development and commercialization of 康柏西普 and other products [6][7] Group 4: Product Development and Sales - The company has secured exclusive distribution rights for the IOPtiMate™ product in China, enhancing its ophthalmic product line [7] - The company aims for restorative growth in traditional Chinese medicine sales and to maintain growth in the chemical medicine sector in line with industry averages [8]

Clinical Trials and Product Development - The global multi-center clinical trial for Kangbaxip (康柏西普) has been initiated in over 30 countries with more than 300 research centers, and over half of the participant recruitment is completed as of August 2019, with expectations to finish by January 2020 [4] - The company is in discussions with global clinical experts and CROs for subsequent clinical plans for other indications, including diabetic macular edema (DME) and retinal vein occlusion (RVO) [4][5] - Kangbaxip is currently approved for three indications in China: wet age-related macular degeneration, vision loss due to polypoidal choroidal vasculopathy (pmCNV), and DME, with ongoing phase III clinical trials [9] Market Competition and Strategy - The final results of the medical insurance negotiations are pending, with expectations for announcements soon [5] - Despite strong competition, the domestic market remains full of opportunities, with trained doctors and patients benefiting from the product as a competitive advantage [5] Financial Instruments and Corporate Governance - On November 8, 2019, the China Securities Regulatory Commission approved the company's application for a public offering of convertible bonds, pending formal approval [5] - The company has implemented a restricted stock incentive plan since its listing in 2015, with evaluations ongoing for future incentive plans based on previous implementations [6] Research and Development Capabilities - The company has established several innovation platforms, including a national recognized enterprise technology center and a postdoctoral research station, focusing on key technology areas such as macromolecular protein drug production and traditional Chinese medicine quality control [7] - The R&D team is structured to support new drug discovery, pharmaceutical development, and regulatory compliance, ensuring a comprehensive knowledge structure [7] Production Capacity and Supply Chain - The production capacity for Kangbaxip is sufficient to meet domestic market demands, with ongoing construction of facilities to support international market supply [8] - The company plans to introduce and register high-quality products that are already available internationally but not yet in the Chinese market [8][9]

Group 1: Product Sales and Market Expansion - The company is focusing on extensive training for doctors and patients to enhance the sales of Conbercept eye injection, aiming to explore untapped markets [4] - The overseas commercialization of Conbercept is a significant priority, with ongoing global multi-center clinical trials expected to reveal its market value [4] - The global multi-center clinical trial for Conbercept involves over 300 research centers across more than 30 countries, with plans to enroll over 2,000 participants, and the enrollment is already over half complete [4] Group 2: Competitive Advantages and Regulatory Preparedness - Conbercept has been recognized by the WHO with the international non-proprietary name "Conbercept," and it has received FDA approval to skip Phase I and II trials, directly proceeding to Phase III, indicating its technical and safety recognition [5] - The company is preparing for the upcoming national medical insurance negotiations by showcasing the advantages of Conbercept and its contributions [6] Group 3: Research and Development Capabilities - The company has established several innovative platforms, including a national recognized technical center and a postdoctoral research station, to enhance its drug development capabilities [6] - Focus areas for R&D include large molecule protein drug technology, standardized quality control for traditional Chinese medicine, green synthesis of chemical raw materials, and new formulations for solid oral drugs [6] - The company has structured its R&D into three main segments: new drug research, product technology center, and medical research center, integrating domestic and international resources for a comprehensive innovation team [6]

Group 1: Company Overview - Chengdu Kanghong Pharmaceutical Group Co., Ltd. focuses on clinical needs and core therapeutic areas, particularly in ophthalmology and neurology [2][4] - The company has developed a series of products, including traditional Chinese medicine and chemical drugs, with an emphasis on filling market gaps and competing internationally [4][5] Group 2: Product Development - The first product, Songling Xuemai Kang capsules, targets hyperlipidemia and hypertension, marking a significant entry into traditional Chinese medicine [4] - Kanghong's Conbercept (Kangbaisipu) has received approval for three indications: wet age-related macular degeneration (wAMD), myopic choroidal neovascularization (pmCNV), and diabetic macular edema (DME) [5][8] - The company is advancing multiple clinical trials, including a global Phase III trial for Conbercept, with over half of the participants enrolled [6][8] Group 3: Financial Strategy - Kanghong plans to issue convertible bonds not exceeding CNY 1.63 billion to fund the industrialization of KH series biological new drugs and international clinical trials for Conbercept [6][8] Group 4: Research and Development - The company has established a robust R&D framework, including a national recognized technical center and a postdoctoral research station, focusing on innovative drug development [9] - Kanghong has implemented an equity incentive plan covering over 400 employees to enhance motivation and performance [9] Group 5: Market Positioning - The company is preparing for the next round of national medical insurance negotiations, aiming to leverage product advantages and contributions to secure favorable outcomes [8]

Group 1: Company Overview - Chengdu Kanghong Pharmaceutical Group Co., Ltd. is focused on developing innovative drugs and has a strong emphasis on self-sustaining capabilities in drug development [2][4]. - The company aims to enhance the pharmaceutical level in China through original technology capabilities [4]. Group 2: Research and Development Strategy - The company is strategically positioning its biopharmaceutical pipeline by focusing on clinically validated targets to improve success rates and reduce risks [5]. - Kanghong is also exploring new mechanisms and molecules, while balancing the development of biosimilars to maintain competitiveness [5][6]. Group 3: Product Development Focus - Kanghong is actively working on products for the treatment of myopia and has ongoing research in this area [5]. - The company is investing in gene therapy, with plans to develop a platform that focuses on major diseases with significant medical needs [6]. Group 4: Team and Innovation Management - The company emphasizes a balanced approach to innovation, assessing both high-risk and low-risk projects in its R&D pipeline [6]. - Kanghong aims to build a capable team that can realize the company's vision, leveraging the experience of its leadership to train team members [6].

Group 1: Company Overview - Chengdu Kanghong Pharmaceutical Group Co., Ltd. is focused on innovative drug research and development, particularly in the central nervous system field [2][4]. - The company has a commitment to long-term goals and sustainable operations, with significant investments in R&D [4]. Group 2: R&D Strategy - The company aims to establish an efficient R&D team and continuously seek specialized talent in relevant fields [5]. - Kanghong's research areas include ophthalmology, central nervous system disorders, and oncology, with a focus on diseases lacking satisfactory treatment options, including rare diseases [6]. Group 3: Project Management and Success Rates - The company employs a balanced project strategy, including First in Class, Best in Class, and Fast Follower projects, to enhance the success rate of R&D [6]. - Kanghong emphasizes the importance of translational medicine, especially for multi-target drugs, to improve clinical research speed and success rates [7]. Group 4: Team and Collaboration - The company has established a collaborative environment with domestic and international research institutions to explore new targets and innovative treatment pathways [6]. - Kanghong's project management is structured to facilitate efficient progress, with independent project management teams formed at the candidate compound stage [7].

Group 1: Company Strategy and Market Position - The company is adapting to changes in the pharmaceutical industry due to new policies and will implement measures accordingly [4] - The promotion of the drug Conbercept (康柏西普) involves extensive training for doctors and patients to increase sales and expand into untapped markets [4] - The overseas commercialization of Conbercept is a key focus, with ongoing global multi-center clinical trials to enhance market value [5] Group 2: Clinical Trials and Product Development - The global multi-center clinical trial for Conbercept involves over 200 research centers across more than 30 countries, with plans to enroll over 2,000 participants [5] - The company is preparing for the upcoming national medical insurance negotiations, aiming to showcase the advantages of Conbercept to achieve favorable outcomes [5] - The company is actively seeking innovative projects globally that align with its strategic goals [6] Group 3: Product Pipeline and Innovations - The company is enhancing its product pipeline based on clinical needs, focusing on core therapeutic areas such as ophthalmology and neurology [6] - Conbercept has received approval for three indications: wet age-related macular degeneration (wAMD), myopic choroidal neovascularization (pmCNV), and diabetic macular edema (DME), with ongoing phase III clinical trials [7] - The company is developing KH906 eye drops for treating trauma and chemical burns, which has received clinical trial approval [7]

证券代码：002773 证券简称：康弘药业 成都康弘药业集团股份有限公司投资者关系活动记录表 | --- | --- | --- | --- | --- | |----------------|-------------------------------------------------------|-------|-------|-------| | | □ 特定对象调研 □分析师会议 | | | | | 投资者关系活动 | □媒体采访 √业绩说明会 | | | | | 类别 | □ 新闻发布会 □路演活动 | | | | | | □现场参观 | | | | | | □ 其他 | | | | | 参与单位名称及 | 投资者 | | | | | | | | | | | 人员姓名 | | | | | | 时间 | 2019 年 5 月 9 日 | | | | | 地点 | " 全 景 · 为： http://rs.p5w.net/c/002773.shtml | （ | | 地 址 | | 上市公司接待人 | 董事长：柯尊洪先生 | | | | | 员姓名 | 董事、总裁：郝晓锋先生 | | | | | | ...

Group 1: Financial Performance and Distribution - The proposal for the profit distribution and capital reserve increase was approved at the board meeting on April 26, 2019, and the shareholders' meeting on May 20, 2019 [4] - The specific date for the rights registration is being coordinated with relevant departments, and further announcements will be made [4] - The company experienced a significant increase in inventory in 2018, attributed to operational needs [5] Group 2: Market and Sales Insights - The sales of traditional Chinese medicine saw a decline in 2018, and the company is working towards recovery [5][11] - The company is actively expanding its market presence and is progressing according to its plans [8] - The revenue share from traditional Chinese medicine has decreased significantly compared to 2017 due to changes in marketing strategies and related policies [10][11] Group 3: Clinical Trials and International Operations - The company has invested $228 million over eight years for Phase III clinical trials in the U.S. and Europe, with significant progress reported [10][11] - The international multi-center Phase III clinical research has received approvals in 25 countries or regions, with over 200 research centers involved [10][11] Group 4: Corporate Governance and Shareholding - The major shareholder's stake is approximately 70%, while another fund holds about 10% of the shares, facing liquidation due to fund expiration [11][12] - The company is committed to optimizing its corporate governance structure in accordance with legal requirements [12]

证券代码：002773 证券简称：康弘药业 成都康弘药业集团股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------------|-----------------------------|------------------------------------| | | | | | 投资者关系活动 | □ | 特定对象调研 □分析师会议 | | 类别 | □媒体采访 □业绩说明会 | | | | □ 新闻发布会 □路演活动 | | | | □现场参观 | | | | √ 其他 上市公司投资者交流会 | | | 参与单位名称及 | | 证券公司、基金公司、资产管理公司等 | | 人员姓名 | | | | 时间 | 2018 年 6 月 1 日 | 10:30-12:00 | | 地点 | 成都市金牛区蜀西路 | 36 号公司一楼会议室。 | | 上市公司接待人 | 董事长：柯尊洪先生 | | | 员姓名 | 董事、总裁：郝晓锋先生 | | | | 董事、常务副总裁：柯潇先生 | | | | | 副总裁、财务总监、董秘：钟建军先生 | 编号：2018-04 1 / 14 ...